By Joe Carrello, The University of Melbourne US President Donald Trump’s proposed tariffs on Australia’s pharmaceutical exports to the United States has raised alarm among industry and government leaders. There are fears that, if implemented, the tariffs could cost the Australian economy up to A$2.8 billion. That’s both in direct exports and as inputs to…
US President Donald Trump has flagged a possible 200 per cent tariff on pharmaceuticals and a 50 per cent tariff on copper, as the ABC reports, with potential significant implications for Australian manufacturers. Speaking to media before a cabinet meeting, Trump said pharmaceutical producers would receive a grace period to move production to the United…
Alan Oppenheim, the Managing Director of family-owned skincare business Ego Pharmaceuticals, was appointed a Member of the Order of Australia (General Division) on Monday. Oppenheim (pictured) has led the company as Managing Director since 1990, according to a statement from Ego, and was its Scientific Director from 1980 – 1990. “I am deeply honoured and…
By Peter Coomber, The University of Queensland and Lisa Nissen, The University of Queensland About 400 medicines are in short supply in Australia. Of these, about 30 are categorised as critical. These are ones with a life-threatening or serious impact on patients, and with no readily available substitutes. Since 2024, there has been a nationwide…
A major breakthrough in liquid catalysis is transforming how essential products are made, making the chemical manufacturing process faster, safer and more sustainable than ever before. Researchers from Monash University, the University of Sydney, and RMIT University have developed a liquid catalyst that could transform chemical production across a range of industries – from pharmaceuticals…
Biome Australia announced its first net profit on Sunday, reporting $96,228 (excluding R&D rebate) for the first half of FY25, alongside record half-year sales revenue of $8.86 million. The microbiome health company reported positive EBITDA of $351,765 for H1 FY25, with Q2 showing an 89 per cent increase to $229,917 compared to Q1. Including R&D…
Radiopharmaceutical medical imaging manufacturer Cyclopharm has revealed a possible new use for its Technegas system – for evaluating the progress of lung transplantation. The use is detailed in a US-based study which highlights the clinical utility and operational benefits of the Technegas technology compared to current US ventilation imaging radiopharmaceuticals used in lung transplant evaluation.…
Pharmaceutical developer Mesoblast’s Revascor (rexlemestrocel-L) drug for children with hypoplastic left heart syndrome (HLHS) has been granted Regenerative Medicine Advanced Therapy designation by the US Food and Drug Administration (FDA). Earlier this year FDA granted REVASCOR both Rare Pediatric Disease Designation (RPDD) and Orphan-Drug Designation (ODD) for congenital heart disease, acknoeledging that the disrase is…
Drug manufacturer AstraZeneca has ordered four more APAS Independence laboratory instruments from AI microbiology automation manufacturer Clever Culture Systems, formally known as LBT Innovations. The order, worth $3.1 million over seven years, adds to the five APAS instruments already in use by the global pharmaceutical company, where they monitor for bacterial contamination in the company’s…
Sparc signs distribution agreement for graphene additive Sparc Technologies has executed a non-binding memorandum of understanding (MoU) with CLP Group subsidiary Chin Leong Construction Systems Pte Ltd. The parties will collaborate on marketing Sparc’s ecosparc additive to CLC’s coatings customers in Southeast Asia. Sparc Managing Director Nick O’Loughlin said: “Sparc…hopes to establish this partnership as…